These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33434512)

  • 21. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Yang J; Gong W
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lorlatinib for the treatment of
    Choo JR; Soo RA
    Expert Rev Anticancer Ther; 2020 Apr; 20(4):233-240. PubMed ID: 32186215
    [No Abstract]   [Full Text] [Related]  

  • 23. Lorlatinib as a treatment for ALK-positive lung cancer.
    Baba K; Goto Y
    Future Oncol; 2022 Aug; 18(24):2745-2766. PubMed ID: 35787143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
    Remon J; Pignataro D; Novello S; Passiglia F
    Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.
    Sakamoto MR; Honce JM; Lindquist DL; Camidge DR
    Clin Lung Cancer; 2019 Mar; 20(2):e133-e136. PubMed ID: 30578110
    [No Abstract]   [Full Text] [Related]  

  • 26. Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.
    Guisier F; Piton N; Bellefleur M; Delberghe N; Avenel G; Angot E; Vittecoq O; Ould-Slimane M; Morisse-Pradier H; Salaun M; Thiberville L
    BMC Cancer; 2020 Jan; 20(1):14. PubMed ID: 31906956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.
    Meng Z; Li T; Wang P; Lizaso A; Huang D
    Cancer Biol Ther; 2021 Jan; 22(1):1-4. PubMed ID: 33380260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib.
    Facchinetti F; Gnetti L; Balestra V; Silva M; Silini EM; Ventura L; Majori M; Bordi P; Tiseo M
    Invest New Drugs; 2019 Apr; 37(2):360-363. PubMed ID: 30066208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.
    Xing P; Wang S; Wang Q; Ma D; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang L; Liang H; Du Y; Zhang Z; Li J
    Target Oncol; 2019 Jun; 14(3):325-333. PubMed ID: 31025247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.
    Patel SP; Pakkala S; Pennell NA; Reckamp KL; Lanzalone S; Polli A; Tarazi J; Robert-Vizcarrondo F
    Oncologist; 2020 Jul; 25(7):562-e1012. PubMed ID: 32048771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
    Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
    Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
    Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
    Solomon BJ; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Shaw AT
    Future Oncol; 2021 Dec; 17(34):4649-4656. PubMed ID: 34585621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
    Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.
    Hida T; Dahlberg SE; Lydon CA; Hatabu H; Johnson BE; Awad MM; Nishino M
    J Thorac Imaging; 2020 Mar; 35(2):101-107. PubMed ID: 30985604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study.
    Gobbini E; Chiari R; Pizzutillo P; Bordi P; Ghilardi L; Pilotto S; Osman G; Cappuzzo F; Cecere F; Riccardi F; Scotti V; Martelli O; Borra G; Maiello E; Rossi A; Graziano P; Gregorc V; Casartelli C; Sergi C; Del Conte A; Delmonte A; Bareggi C; Cortinovis D; Rizzo P; Tabbò F; Rossi G; Bria E; Galetta D; Tiseo M; Di Maio M; Novello S
    Clin Transl Oncol; 2020 Mar; 22(3):294-301. PubMed ID: 31630357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of one lung adenocarcinoma patient harboring a novel FAM179A-ALK (F1, A19) rearrangement responding to lorlatinib treatment.
    Yan J; Zhou X; Pan D
    Lung Cancer; 2020 Sep; 147():26-29. PubMed ID: 32652371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
    Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
    J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.